Older people at highest risk of death are least likely to receive effective COVID-19 treatment
![](./upload/news/image_1644164056_1461583.jpg)
People over age 65 at the highest risk for severe COVID-19 have often been the least likely to receive monoclonal antibodies (mAbs)—a highly effective treatment for the disease—both across and within U.S. states, according to new research co-authored by researchers from Harvard T.H. Chan School of Public Health.